Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.
In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed. Ninety-five HIV-positive patients were followed for 562 days, and 37 lost at least 50 CD4 cells, with a median delay of 274 days. Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.
Lacombe
Karine
K
Assistance Publique, Hôpitaux de Paris, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris F-75012, France.
Pacanowski
Jérôme
J
Meynard
Jean-Luc
JL
Trylesinski
Aldo
A
Girard
Pierre-Marie
PM
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes; D016049:Didanosine / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008231:Lymphopenia / Q000139:chemically induced*; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects*; D012307:Risk Factors; D000068698:Tenofovir
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine; D016049:Didanosine